ATLANTA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a clinical-stage biotechnology company developing new medicines to treat pain and ...
On September 29, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a royalty-free, global license deal with Serpin Pharma for SP16 for the management of cancer related pain (CRP), including a ...
FDA IND clearance enables a phase 1b evaluation of SP16 in chemotherapy-induced pain and peripheral neuropathy, with enrollment planned for mid-2026 at the University of Virginia. Proposed mechanisms ...
(RTTNews) - Dogwood Therapeutics, Inc. (DWTX) said, in an all-stock transaction, it has secured a royalty free, global license to develop Serpin Pharma's intravenous formulation of SP16 to manage ...
The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected to commence in the middle of 2026 at the University of Virginia “FDA acceptance of our SP16 IND ...
All-Stock Licensing Deal for Treatment of Cancer Related Pain On September 29, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a royalty-free, global license deal with Serpin Pharma for SP16 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results